Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy.

Osteoporosis poses a significant public health issue. In recent years, International and National Societies have developed Guidelines for the diagnosis and treatment of this disorder, with an effort of adapting specific tools for risk assessment on the peculiar characteristics of a given population. The Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS) has recently revised the previously published Guidelines on the diagnosis, risk-assessment, prevention and management of idiopathic postmenopausal osteoporosis, also focusing on male and secondary osteoporosis. These recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on leading experts' experience and opinion, and on good clinical practice. Nonetheless, the practical management of osteoporosis is greatly influenced by economic reimbursement policies, particularly for secondary forms of osteoporosis. The refinement of risk assessment, the long-term treatment of osteoporosis and the prevention and management of disease-associated bone loss constitute open issues.

[1]  D. Bauer,et al.  Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. , 2013, The American journal of medicine.

[2]  P. Camacho,et al.  Secondary causes of osteoporosis. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  E. Biver.  Use of bone turnover markers in clinical practice , 2012, Current opinion in endocrinology, diabetes, and obesity.

[4]  Naoto Endo,et al.  Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.

[5]  C. Marcocci,et al.  Bone disease in primary hyperparathyrodism , 2012, Therapeutic advances in musculoskeletal disease.

[6]  Eugene McCloskey,et al.  FRAX updates 2012 , 2012, Current opinion in rheumatology.

[7]  C. Zerbini,et al.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. , 2012, Revista brasileira de reumatologia.

[8]  R. Eastell,et al.  Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  E. Lespessailles,et al.  2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. , 2012, Joint, bone, spine : revue du rhumatisme.

[10]  E. Kelepouris,et al.  Bone Disease in Organ Transplant Patients: Pathogenesis and Management , 2012, Postgraduate medicine.

[11]  P. Hadji,et al.  Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES) , 2012, Breast Cancer Research and Treatment.

[12]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[13]  Peter J. Schmidt,et al.  The 2022 hormone therapy position statement of The North American Menopause Society , 2022, Menopause.

[14]  G. Lyritis,et al.  2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. , 2012, Journal of musculoskeletal & neuronal interactions.

[15]  J. J. Jiménez Moleón,et al.  [Clinical practice guidelines for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Bone Metabolism Working Group of the Spanish Society of Endocrinology]. , 2012, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

[16]  H. Powell,et al.  Adherence to the U.S. Preventive Services Task Force 2002 osteoporosis screening guidelines in academic primary care settings. , 2012, Journal of women's health.

[17]  J. Reginster.  Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis , 2012, Drugs.

[18]  L. Melton,et al.  The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008 , 2012, Osteoporosis International.

[19]  R. Rizzoli,et al.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper , 2012, Osteoporosis International.

[20]  David A Hanley,et al.  Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk , 2011, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[21]  B. Edwards,et al.  Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. , 2011, Journal of the American Dental Association.

[22]  J. Nolla,et al.  [2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis]. , 2011, Reumatologia clinica.

[23]  H. Raspe,et al.  [Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists]. , 2011, Zeitschrift fur Rheumatologie.

[24]  M. Suarez‐Almazor,et al.  Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups , 2011, Osteoporosis International.

[25]  J. Li-Yu,et al.  Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines , 2011, International journal of rheumatic diseases.

[26]  C. Cooper,et al.  Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[27]  U. P. S. T. Force,et al.  Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement , 2011, Annals of Internal Medicine.

[28]  G. Rebecca,et al.  American College of Rheumatology 2010 Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2011 .

[29]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[30]  N. Watts,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[31]  M. Brandi.  Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis , 2010, Current medical research and opinion.

[32]  J. Reginster,et al.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club , 2010, Osteoporosis International.

[33]  L. Lenchik,et al.  Dual X-ray absorptiometry in today's clinical practice. , 2010, Radiologic clinics of North America.

[34]  G. Guglielmi,et al.  Quantitative ultrasound in osteoporosis and bone metabolism pathologies. , 2010, Radiologic clinics of North America.

[35]  J. Osieleniec,et al.  Guidelines on the Diagnosis of Osteoporosis and Assessment of Fracture Risk in Poland of III Central European Congress on Osteoporosis and Osteoarthritis, XV Congress of the Polish Osteoarthrology Society and Polish Foundation of Osteoporosis. , 2010, Ortopedia, traumatologia, rehabilitacja.

[36]  G. Guglielmi,et al.  Vertebral morphometry. , 2010, Radiologic clinics of North America.

[37]  C. Marcocci,et al.  [Guidelines for the diagnosis, prevention and treatment of osteoporosis]. , 2011, Reumatismo.

[38]  L. Idolazzi,et al.  Neridronic acid for the treatment of bone metabolic diseases , 2009, Expert opinion on drug metabolism & toxicology.

[39]  Judith E. Adams,et al.  Quantitative computed tomography. , 2009, European journal of radiology.

[40]  J. Bilezikian,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[41]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[42]  M. Kleerekoper,et al.  Secondary osteoporosis: a review of the recent evidence. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[43]  A. Gibofsky.  American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[44]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .